您的位置: 首页 > 2016年9月 第47卷 第5期 > 文字全文
2023年7月 第38卷 第7期11
目录

Th17细胞在不同国际预后指数组DLBCL中的表达及意义

Expression of Th17 cells in different DLBCL IPI groups and its significance

来源期刊: 广州医药 | 14-16 发布时间:2021-12-02 收稿时间:2025/11/13 16:54:35 阅读量:30
作者:
关键词:
弥漫大B细胞淋巴瘤Th17细胞国际预后指数
DLBCLTh17 cellIPI
DOI:
10.3969/j.issn.1000-8535.2016.05.005
收稿时间:
2016-06-07 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 探讨初诊的弥漫大B细胞淋巴瘤(DLBCL)患者外周血Th17细胞的表达与国际预后指标(IPI)之间关系。方法 初诊DLBCL组(n=45)按照国际预后指数(IPI)积分分为4组,采用ELISA和流式细胞术检测各个DLBCL组与正常对照组(n=43)的外周血中IL-17的浓度以及Th17阳性细胞比例,比较各组数值间的差异,并分析IPI的5个指标与IL-17的浓度以及Th17阳性细胞比例的相关性。结果 DLBCL中高危组与高危组的IL-17的浓度以及Th17阳性细胞比例较正常对照组及其他IPI组降低,有显著性差异;DLBCL四组的IL-17的浓度以及Th17阳性细胞比例均低于正常对照组;且可见随着IPI分组的增高,IL-17的浓度以及Th17阳性细胞比例呈降低的趋势;IPI指标中年龄、临床分期、全身状态与Th17细胞的表达有相关性。结论 初诊DLBCL患者外周血Th17细胞的表达与国际预后指标有关系;随着IPI积分的增加,DLBCL患者Th17细胞表达下降;临床上对于年龄60岁以上、临床分期Ⅲ期以上、长期卧床及需别人照顾的患者更要注意监测其外周血Th17细胞的表达情况。
Objective To explore the relationship between the international prognosis indexes(IPI) and the Th17 cells expression in DLBCL patients. Methods DLBCL patients (n=45) were divided into 4 groups according to IPI score, peripheral blood were taken from each person in DLBCL groups and normal group. We used ELISA to test IL-17 and flow cytometry (FCM) to examine the Th17 positive cells. We compared the value of each group, and analyzed the relativity of IPI and Th17 cells' expression. Results Th17 cells' expression level in middle-high risk group and high risk group were higher than that in normal group and other IPI groups; Th17 cells' expression level in DLBCL groups were all lower than that in normal group; Th17 cells decreased while IPI score increased; Age, clinical stage and general body state have the relativity with DLBCL patients' Th17 cells expression level. Conclusion Th17 cells in DLBCL patients has the relativity with prognosis index. In our clinical diagnosis and treatment, we need to pay more attention to those patients who are over 60 years old, or whose clinical stage is above Ⅲ phase, or who need to stay on bed for a long time and need other peoples' help .
1、 CANTINI G, PISATI F, MASTROPIETRO A, et al. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment[J]. Cancer Immunol Immunother,2011,60(12):1739-1750. CANTINI G, PISATI F, MASTROPIETRO A, et al. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment[J]. Cancer Immunol Immunother,2011,60(12):1739-1750.
2、 KRYCZEK I, BANERJEE M, CHENG P, et al. Phenotype, distribution, generation,and functional and clinical relevance of Th17 cells in the human tumorenvironments[J]. Blood,2009,114(6):1141-1149. KRYCZEK I, BANERJEE M, CHENG P, et al. Phenotype, distribution, generation,and functional and clinical relevance of Th17 cells in the human tumorenvironments[J]. Blood,2009,114(6):1141-1149.
3、 MURANSKI P, NICHOLAS P. Does IL-17 promote tumor grooth[J]. Blood,2009,114(2):357-359. MURANSKI P, NICHOLAS P. Does IL-17 promote tumor grooth[J]. Blood,2009,114(2):357-359.
4、 MURANSKI P, BONI A, ANTONY PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma[J]. Blood,2008,112(2): 362-373. MURANSKI P, BONI A, ANTONY PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma[J]. Blood,2008,112(2): 362-373.
5、 MIYAHARA Y, ODUNSI K, CHEN W, et al. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer[J]. Proc Natl Acad Sci USA,2008,105(40):15505-15510. MIYAHARA Y, ODUNSI K, CHEN W, et al. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer[J]. Proc Natl Acad Sci USA,2008,105(40):15505-15510.
6、 NUMASAKI M, WATANABE M, SUZUKI T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis[J]. J Immunol,2005,175:6177-6189. NUMASAKI M, WATANABE M, SUZUKI T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis[J]. J Immunol,2005,175:6177-6189.
7、 张晓君,王正昕,傅志仁. Th17 型细胞在移植排斥反应中的研究进展[J]. 中华器官移植杂志,2010,31(3):187-189. 张晓君,王正昕,傅志仁. Th17 型细胞在移植排斥反应中的研究进展[J]. 中华器官移植杂志,2010,31(3):187-189.
8、 钟道清,罗育武,罗权.寻常性银屑病患者外周血Th1和Th17细胞亚群的研究[J]. 广州医药,2012,43(3):16-18. 钟道清,罗育武,罗权.寻常性银屑病患者外周血Th1和Th17细胞亚群的研究[J]. 广州医药,2012,43(3):16-18.
9、 涂峰,李贵良,苏星烽.孟鲁司特对哮喘患者外周血Th1/Th2平衡以及外周血炎症因子水平的影响[J]. 广州医药,2016,47(1):78-80. 涂峰,李贵良,苏星烽.孟鲁司特对哮喘患者外周血Th1/Th2平衡以及外周血炎症因子水平的影响[J]. 广州医药,2016,47(1):78-80.
10、 陈灏珠.实用内科学[M]. 12版. 北京: 人民卫生出版社,2005: 2046-2410. 陈灏珠.实用内科学[M]. 12版. 北京: 人民卫生出版社,2005: 2046-2410.
11、 胡利娟,周旻,尹一子,等. 复发苦参组注射液联合化疗治疗淋巴瘤临床疗效与安全性的Meta分析[J]. 现代医院,2015,15(12):21-24. 胡利娟,周旻,尹一子,等. 复发苦参组注射液联合化疗治疗淋巴瘤临床疗效与安全性的Meta分析[J]. 现代医院,2015,15(12):21-24.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录